|
Synonyms: HTT AO | IONIS-HTTRx | ISIS 443139 | ISIS-443139 | ISIS-HTT Rx | RG-6042 | RG6042 | RO7234292
Compound class:
Nucleic acid
Comment: Tominersen (ISIS-443139, RG-6042) is an allele-nonselective antisense oligonucleotide (ASO) gapmer [1] that was intended to reduce production of huntingtin (HTT) protein (mutant and wild-type).
Chemically tominersen is a 20-mer 2'-O-methoxyethyl (2'-MOE) oligonucleotide with a phosphorothioate (PS) backbone. Full sequence is: all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl- (3'→5')-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine |
| No information available. |
Summary of Clinical Use ![]() |
| Safety of tominersen (ISIS-443139, RG-6042) was demonstrated in clinical trial NCT02519036 [3]. It reached phase 3 investigations as a treatment for Huntington's disease [2], but development was discontinued in mid-2026 due to lack of efficacy to either improve clinical symptoms or slow disease progression. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02519036 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease | Phase 1/Phase 2 Interventional | Ionis Pharmaceuticals, Inc. | ||
| NCT03342053 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) | Phase 2 Interventional | Hoffmann-La Roche | ||
| NCT03842969 | An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies | Phase 3 Interventional | Hoffmann-La Roche | ||
| NCT03761849 | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease | Phase 3 Interventional | Hoffmann-La Roche | ||